Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-27
2007-11-27
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S375000
Reexamination Certificate
active
11335669
ABSTRACT:
The present invention provides a compound selectively activating PPARα, which is useful as a medicament. The present invention is specifically directed to a benzoic acid derivative represented by the following general formula (1):wherein A represents an oxygen atom, a nitrogen atom, or a sulfur atom; R represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyl-alkyl group, an aryl group, an aryl-alkyl group an aryl-oxy-alkyl group, a pyridyl-alkyl group, an alkoxycarbonyl-alkyl group, or a carboxy-alkyl group; X represents an oxygen atom, an NH group, or an S(O)ngroup (wherein n represents an integer of 0, 1, or 2); and m represents an integer from 2 to 8; or a salt thereof. The present invention also provides a medicament comprising the benzoic acid derivative or the salt thereof as an active ingredient.
REFERENCES:
patent: 5741796 (1998-04-01), Hartman et al.
patent: 6653334 (2003-11-01), Yamazaki et al.
patent: 2005/0070532 (2005-03-01), Liu et al.
patent: 2005/0101636 (2005-05-01), Yamazaki et al.
patent: 10-501222 (1998-02-01), None
patent: WO 02/46176 (2002-06-01), None
patent: WO 2004/000762 (2003-12-01), None
patent: WO 2004/092130 (2004-10-01), None
patent: WO 2004/093879 (2004-11-01), None
Curtis et al., The Journal of the American Board of Family Practice, vol. 18, pp. 37-43, (2005).
Isabelle Issemann, et al., “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators”, NATURE, vol. 347, Oct. 18, 1990, pp. 645-650.
Christine Dreyer, et al., “Control of the Peroxisomal β-Oxidation Pathway by a Novel Family of Nuclear Hormone Receptors”, Cell, vol. 68, Mar. 6, 1992, pp. 879-887.
“A Unified Nomenclature System for the Nuclear Receptor Superfamily”, Cell, vol. 97, Apr. 16, 1999, pp. 161-163.
Kristina Schoonjans, et al., “The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation”, Biochimica et Biophysica Acta 1302, 1996, pp. 93-109.
Timothy M. Willson, et al., “The PPARs: From Orphan Receptors to Drug Discovery”, Journal of Medicinal Chemistry, vol. 43, No. 4, Feb. 24, 2000, pp. 527-550.
Frank J. Gonzalez, et al., “Mechanism of Action of the Nongenotoxic Peroxisome Proliferators: Role of the Peroxisome Proliferator-Activated Receptor α”, Journal of the National Center Institute, vol. 90, No. 22, Nov. 18, 1998, pp. 1702-1709.
Jean-Charles Fruchart, et al., “Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis”, Current Opinion in Lipidology, 10, 1999, pp. 245-257.
Johan Auwerx, et al., “Regulation of Triglyceride Metabolism by PPARs: Fibrates and Thiazolidinediones have Distinct Effects”, Journal of Atherosclerosis and Thrombosis, vol. 3, No. 2, 1996, pp. 81-89.
Bart Staels, et al., “Role of PPAR in the Pharmacological Regulation of Lipoprotein Metabolism by Fibrates and Thiazolidinediones”, Current Pharmaceutical Design, vol. 3, No. 1, 1997, pp. 1-14.
Ines Pineda, et al., “Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging”, Current Opinion in Lipidology, 10, 1999, pp. 151-159.
Joseph Vamecq, et al., “Medical significance of peroxisome proliferator-activated receptors”, The Lancet, vol. 354, Jul. 10, 1999, pp. 141-148.
Sander J. Robins, “PPARα ligands and clinical trials: cardiovascular risk reduction with fibrates”, Journal of Cardiovascular Risk, vol. 8, No. 4, 2001, pp. 195-201.
Juergen M. Lehmann, et al., “An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)*”, The Journal of Biological Chemistry, vol. 270, No. 22, 1995, pp. 12953-12956.
Joel Berger, et al., “Thiazolidinediones Produce a Conformational Change in Peroxisomal Proliferator-Activated-γ: Binding and Activation Correlate with Antidiabetic Actions in db/db Mice”, Endocrinology, vol. 137, No. 10, 1996, pp. 4189-4195.
Mauricio J. Reginato, et al., “Mechanisms by which Thiazolidinediones Enhance Insulin Action”, Trend Endocrinol. Metab., vol. 10, No. 1, 1999, pp. 9-13.
Akira Okuno, et al., “Troglitazone Increases the Number of Small Adipocytes without the Change of White Adipose Tissue Mass in Obese Zucker Rates”, J. Clin. Invest., vol. 101, No. 6, Mar. 1998, pp. 1354-1361.
Sir-Pietrie, et al., “Glitazones and NIDDM”, The Lancet, vol. 349, Mar. 29, 1997, p. 952.
Jennifer L. Oberfield, et al., “A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation”, Proc. Natl. Acad. Sci. vol. 96, May 1999, pp. 6102-6106.
Harold M. Wright, et al., “A Synthetic Antagonist for the Peroxisome Proliferator-activated Receptor γ Inhibits Adipocyte Differentiation”, The Journal of Biological Chemistry, vol. 275, No. 3, Jan. 21, 2000, pp. 1873-1877.
Toshimasa Yamauchi, et al., “Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes”, The Journal of Clinical Investigation, vol. 108, No. 7, Oct. 2001, pp. 1001-1013.
Didier Auboeuf, et al., “Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator-Activated Receptors and Liver X Receptor-α in Humans”, DIABETES, vol. 46, Aug. 1997, pp. 1319-1327.
William R. Oliver, Jr., et al., “A selective peroxisome proliferator-activated receptor σ agonist promotes reverse cholesterol transport”, PNAS, vol. 98, No. 9, Apr. 24, 2001, pp. 5306-5311.
Yong-Xu Wang, et al., “Peroxisome-Proliferator-Activated Receptor σ Activates Fat Metabolism to Prevent Obesity”, Cell, vol. 113, Apr. 18, 2003, pp. 159-170.
Helen Vosper, et al., “The Peroxisome Proliferator-activated Receptor σ Promotes Lipid Accumulation in Human Macrophages*”, The Journal of Biological Chemistry, vol. 276, No. 47, Nov. 23, 2001, pp. 44258-44265.
Yaacov Barak, et al., “Effects of peroxisome proliferator-activated receptor σ on placentation, adiposity, and colorectal cancer”, PNAS, vol. 99, No. 1, Jan. 8, 2002, pp. 303-308.
Barrie C. C. Cantello, et al., “[[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents”, Journal of Medicinal Chemistry, vol. 37, No. 23, 1994, pp. 3977-3985.
Abe Kazutoyo
Nishikawa Masahiro
Okuda Ayumu
Ozawa Hidefumi
Toma Tsutomu
Kowa Co. Ltd.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Stockton Laura L.
LandOfFree
PPAR-activating compound does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PPAR-activating compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PPAR-activating compound will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3810288